July 16th, 2014
HPS2-THRIVE: The Final Chapter in the Niacin Story?
Nicholas Downing, MD and Harlan M. Krumholz, MD, SM
Findings from HPS2-THRIVE raise uncomfortable questions for physicians.
September 19th, 2012
An Ad That Doesn’t Tell the Entire Story — Part 2: Niaspan
Harlan M. Krumholz, MD, SM
A print ad for Niaspan focuses only on how it raises HDL-cholesterol levels, with no mention of the lack of benefit in improving outcomes.
May 26th, 2011
NHLBI Stops the AIM-HIGH Trial of Niacin
Larry Husten, PHD
The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health) trial of niacin has been stopped early by the NHLBI. The trial was designed to test the addition of high-dose, extended-release niacin to statins in people at risk for CV events who had well-controlled LDL but low HDL and elevated […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?